Posted by Jeff Wilder on Oct 30th, 2024
AnaptysBio (NASDAQ:ANAB – Get Free Report) had its price target increased by stock analysts at UBS Group from $23.00 to $33.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “neutral”...
More of this article »